AstraZeneca hold internal talks for Medivation takeover – reports
pharmafile | April 18, 2016 | News story | Manufacturing and Production, Sales and Marketing | 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug company, Medivation (NASDAQ: MDVN).
According to the Sunday Times, the company has yet to make a formal offer for the San-Francisco-based Medivation, which boasts a market cap of $8.38 billion. The firm bases much of its focus in oncology treatments.
AstraZeneca are said to be close to making an offer. This news comes a week after Bloomberg reported that Medivation had rejected an offer from Sanofi (EPA: SAN). Reports also suggest that Medivation had employed the services of Wall Street bank JP Morgan to help fend off unwanted takeovers. Shares in the company have risen as high as 10% in the past week.
Mergers (and failed mergers) are the topic du jour in the pharmaceutical industry this month after the failed Pfizer/Allergan inversion made headlines.
Sean Murray
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …